Our results also established that inhibition of CK1ε protects hypo-phosphorylated RB1 from degradation and simultaneously abolishes CDK4/6i-induced CDK6 accumulation, thereby providing a potential therapeutic strategy for breast cancer patients (Fig. 5j). Here, RB1 is linked to breast carcinoma.